Home > Search Results: Journal of Dermatological Treatment
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
UAB Digital Repository of Documents 4 records found  Search took 0.02 seconds. 
1.
10 p, 1.8 MB Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis / Reich, Kristian (University Medical Center Hamburg-Eppendorf) ; Conrad, Curdin (University Hospital Lausanne CHUV) ; Kristensen, Lars Erik (Lund University) ; Smith, Saxon D. (The University of Sydney) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Rich, Phoebe (Oregon Dermatology and Research Center) ; Sapin, Christophe (Eli Lilly and Company) ; Holzkaemper, Thorsten (Eli Lilly and Company) ; Koppelhus, Uffe (Eli Lilly and Company) ; Schuster, Christopher (Medical University of Vienna) ; Universitat Autònoma de Barcelona
Nail psoriasis (NP) is common and of high importance in patients with psoriasis. Complete resolution of NP at week 24‒26 is an unambiguous nail outcome accessible for indirect treatment comparison of biologics. [...]
2022 - 10.1080/09546634.2021.1892024
Journal of Dermatological Treatment, Vol. 33 Núm. 3 (2022) , p. 1652-1660  
Detailed record - Creative Commons
2.
10 p, 1.7 MB Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis / Papp, Kim A (K Papp Clinical Research) ; Thoning, Henrik (LEO Pharma) ; Gerdes, Sascha (Center for Inflammatory Skin Diseases. Dept. of Dermatology. Venereology and Allergology. University Medical Center Schleswig-Holstein) ; Megna, Matteo (Section of Dermatology. Dept. of Clinical Medicine and Surgery. University of Naples Federico II) ; Brandi, Henrik (LEO Pharma) ; Jablonski Bernasconi, Marie Y. (LEO Pharma) ; Yélamos, Oriol (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
Background and objectives: Once-daily, fixed-combination calcipotriol 50 μg/g (Cal) plus betamethasone dipropionate 0. 5 mg/g (BD) is available in aerosol foam and cream formulations. As no head-to-head data are available, we use a matching-adjusted indirect comparison (MAIC) approach to compare Cal/BD foam and cream. [...]
2022 - 10.1080/09546634.2022.2095330
Journal of Dermatological Treatment, Vol. 33 Núm. 7 (2022) , p. 3005-3013  
Detailed record - Creative Commons
3.
10 p, 1.5 MB Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis : analysis of pooled data from the randomized trials SOLO 1 and SOLO 2 / Cork, M.J. (University of Sheffield Medical School) ; Eckert, L. (Sanofi) ; Simpson, E.L. (Oregon Health & Science University) ; Armstrong, A. (Keck School of Medicine at USC. University of Southern California) ; Barbarot, Sebastien (CHU Hôtel-Dieu) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Girolomoni, G. (University of Verona) ; de Bruin-Weller, Marjolein (University Medical Center Utrecht) ; Wollenberg, A. (Klinikum der Universität München) ; Kataoka, Y. (Osaka Habikino Medical Center) ; Remitz, A. (Helsinki University Central Hospital) ; Beissert, Stefan (Technische Universität Dresden) ; Mastey, V. (Regeneron Pharmaceuticals Inc.) ; Ardeleanu, Marius (Regeneron Pharmaceuticals Inc.) ; Chen, Z. (Regeneron Pharmaceuticals Inc.) ; Gadkari, A. (Regeneron Pharmaceuticals Inc.) ; Chao, J. (Regeneron Pharmaceuticals Inc.) ; Universitat Autònoma de Barcelona
Atopic dermatitis (AD) profoundly affects quality of life (QoL). Dupilumab significantly improves clinical outcomes, is well tolerated, and approved to treat inadequately controlled moderate-to-severe AD in adults; however, its effect on patient-reported outcomes (PROs) is not fully characterized. [...]
2020 - 10.1080/09546634.2019.1612836
Journal of Dermatological Treatment, Vol. 31 Núm. 6 (17 2020) , p. 606-614  
Detailed record - Creative Commons
4.
9 p, 2.0 MB Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis : an analysis from VOYAGE 1 and VOYAGE 2 / Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Wu, Jashin (Dermatology Research and Education Foundation) ; Gooderham, Melinda (SKiN Centre for Dermatology and Department of Medicine. Queen's University) ; You, Yin (Biostatistics. Immunology. Janssen Research & Development. LLC) ; Shen, Yaung-Kaung (Biostatistics. Immunology. Janssen Research & Development. LLC) ; Randazzo, Bruce (Clinical Research. Janssen Research & Development. LLC) ; Kerdel, Francisco (Florida Academic Dermatology Centers)
Introduction: In VOYAGE 1 (NCT02207231) and VOYAGE 2 (NCT02207244), guselkumab, an interleukin-23 blocker, was safe and effective in patients with moderate-to-severe plaque psoriasis. Methods: Patients who self-identified as Hispanic (n = 117) or non-Hispanic (n = 1686) were randomized to guselkumab, placebo, or adalimumab. [...]
2021 - 10.1080/09546634.2019.1679336
Journal of Dermatological Treatment, Vol. 32 Núm. 5 (2021) , p. 484-491  
Detailed record - Creative Commons

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with